$10.86 Million in Sales Expected for Denali Therapeutics Inc (NASDAQ:DNLI) This Quarter

Brokerages expect Denali Therapeutics Inc (NASDAQ:DNLI) to post $10.86 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Denali Therapeutics’ earnings, with estimates ranging from $1.20 million to $23.50 million. Denali Therapeutics posted sales of $1.20 million in the same quarter last year, which suggests a positive year-over-year growth rate of 805%. The firm is expected to announce its next quarterly earnings results on Thursday, November 14th.

On average, analysts expect that Denali Therapeutics will report full-year sales of $33.72 million for the current year, with estimates ranging from $10.79 million to $83.79 million. For the next fiscal year, analysts forecast that the firm will report sales of $54.60 million, with estimates ranging from $10.79 million to $175.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Denali Therapeutics.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.15). Denali Therapeutics had a negative net margin of 40.78% and a negative return on equity of 11.03%. The company had revenue of $4.20 million during the quarter, compared to the consensus estimate of $4.52 million.

A number of equities analysts have recently issued reports on the stock. Nomura assumed coverage on shares of Denali Therapeutics in a research note on Friday, September 13th. They issued a “buy” rating and a $35.00 price objective for the company. TheStreet cut shares of Denali Therapeutics from a “c-” rating to a “d” rating in a research note on Thursday, June 13th. Wedbush assumed coverage on shares of Denali Therapeutics in a research note on Wednesday, September 25th. They issued a “neutral” rating and a $19.00 price objective for the company. They noted that the move was a valuation call. BTIG Research assumed coverage on shares of Denali Therapeutics in a research note on Friday, August 9th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 27th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $27.25.

Shares of DNLI stock traded up $0.39 during mid-day trading on Thursday, reaching $15.20. The company’s stock had a trading volume of 192,494 shares, compared to its average volume of 352,003. Denali Therapeutics has a 1-year low of $13.78 and a 1-year high of $28.86. The company has a market cap of $1.46 billion, a P/E ratio of -38.97 and a beta of 2.15. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.66 and a current ratio of 10.65. The firm’s 50-day moving average is $17.38 and its two-hundred day moving average is $20.51.

In related news, CEO Ryan J. Watts sold 8,581 shares of the stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $18.05, for a total transaction of $154,887.05. Following the completion of the sale, the chief executive officer now owns 12,505 shares in the company, valued at approximately $225,715.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Alexander O. Schuth sold 7,500 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.16, for a total transaction of $136,200.00. In the last 90 days, insiders sold 23,581 shares of company stock valued at $432,162. Corporate insiders own 21.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. TD Asset Management Inc. increased its position in shares of Denali Therapeutics by 2.2% during the 1st quarter. TD Asset Management Inc. now owns 23,400 shares of the company’s stock worth $543,000 after purchasing an additional 500 shares in the last quarter. Virtus ETF Advisers LLC increased its position in shares of Denali Therapeutics by 7.9% during the 2nd quarter. Virtus ETF Advisers LLC now owns 14,246 shares of the company’s stock worth $296,000 after purchasing an additional 1,045 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Denali Therapeutics by 19.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 13,170 shares of the company’s stock worth $271,000 after purchasing an additional 2,101 shares in the last quarter. Swiss National Bank increased its position in shares of Denali Therapeutics by 2.0% during the 2nd quarter. Swiss National Bank now owns 114,800 shares of the company’s stock worth $2,383,000 after purchasing an additional 2,300 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its position in shares of Denali Therapeutics by 19.3% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 20,555 shares of the company’s stock worth $427,000 after purchasing an additional 3,330 shares in the last quarter. Institutional investors and hedge funds own 73.91% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Further Reading: How to Invest in Marijuana Stocks

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.